Cardiotoxicity linked to anticancer agents and cardioprotective strategy

• Published in: Archives of pharmacal research 2022-10, Vol.45 (10), p.704-730
• Main Authors: Khairnar, Shraddha I., Kulkarni, Yogesh A., Singh, Kavita
• Format: Article
• Language: English
• Subjects: Medicine; Pharmacology/Toxicology; Pharmacy; Review
• ISSN: 0253-6269; 1976-3786
• DOI: 10.1007/s12272-022-01411-4

Chemotherapy is a main treatment for cancer, and it benefits patients by controlling cancer relapse and metastasis, thereby leading to an increase in the overall survival rate. However, this treatment is associated with mild to severe side effects, one of which is cardiotoxicity. The severity of cardiotoxicity, a leading cause of cardiovascular diseases, depends on the type of cancer therapy employed and the time required for its management. A chemotherapeutic agent is used either alone or in combination with other drugs for cancer treatment. The exact mechanism of chemotherapeutic agent-induced cardiotoxicity remains unclear, although it is likely to be multifactorial and to include oxidative stress, apoptosis, and inflammation. There are many approaches to avoid the untoward effects of chemotherapeutic agents. However, the available options for cardiac protection are minimal, and they include renin-angiotensin system blockers, beta-blockers, herbal drugs, or iron chelators such as dexrazoxane. The present review provides information on the molecular mechanism of chemotherapy-induced myocardial infarction and cardiotoxicity along with scientifically studied synthetic molecules, herbal extracts, and natural products to manage chemotherapy-induced cardiotoxicity.